Journal Article Review Epublish 2 citations
PubMed: 40521058 DOI: 10.5114/ada.2025.149438
The association between metabolic syndrome and vitiligo: a systematic review.
Postepy Dermatol Alergol 42(2):134-142
Authors: Aleksandra Białczyk, Barbara Kamińska, Rafał Czajkowski
Affiliations
- Department of Dermatology and Venereology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Abstract
Vitiligo is a chronic autoimmune disorder linked to systemic inflammation, oxidative stress, and metabolic dysregulation, including metabolic syndrome (MetS). This review examines the shared mechanisms underlying vitiligo and MetS, highlighting oxidative stress, pro-inflammatory cytokines, and lipid dysregulation as central contributors. A systematic analysis of 23 studies found association between vitiligo and MetS, though variations exist based on the disease type, severity, and duration. Emerging therapies, such as statins and thiazolidinediones demonstrate potential for managing vitiligo and its metabolic risks by targeting oxidative and inflammatory pathways. While animal and in vitro studies show promise, clinical outcomes are inconsistent, with safety concerns limiting systemic treatments.
MeSH
Vitiligo, Stress, Physiological, Oxidative Stress, Therapeutics, Hydroxymethylglutaryl-Coa Reductase Inhibitors, Metabolic Syndrome, Thiazolidinediones
Cited by
- Leflunomide-Mediated Immunomodulation Inhibits Lesion Progression in a Vitiligo Mouse Model. Int J Mol Sci, 2025
- Lipidome Complexity in Physiological and Pathological Skin Pigmentation. Int J Mol Sci, 2025